Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.35 |
| ▸ | TRPC7 | Q9HCX4 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792515 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL6794409 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL6798193 | 0.77 | ALDH1A1 (0.41) | SMN1; SMN2CYP2C19HTTMEN1KMT2A | |
| SCHEMBL6793950 | 0.77 | CCNA2 (0.39) | CYP2C19NPC1RAB9ALMNAF2 | |
| SCHEMBL6793395 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL6788861 | 0.74 | CCNA2 (0.37) | SMN1; SMN2CYP2C19MEN1KMT2ALMNA | |
| SCHEMBL6789502 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL6790820 | 0.70 | CCNA2 (0.36) | — | |
| SCHEMBL6792562 | 0.68 | AURKA (0.51) | CYP2C19NPC1RAB9AHTTMEN1 | |
| SCHEMBL6794842 | 0.68 | OPRD1 (0.35) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | SMN1; SMN2 4333/4885CYP2C19 997/4885NPC1 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.